Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-oral shorter regimens for MDR/RR-TB in Pakistan
ISRCTN17334530Phase 3Completed
- Sponsor
- World Health Organization
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of linezolid and bedaquiline in multidrug-resistant tuberculosis (MDR-TB) and Tuberculosis (TB) (2 arms), sponsored by World Health Organization. Primary endpoints: Treatment effectiveness and Treatment safety. Started Jul 2020; status: completed.
02
Drugs
linezolidbedaquiline
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)Tuberculosis (TB)
Beyond the preview
Go deeper on ISRCTN17334530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17334530.